|
Dallas–Fort Worth, TX Press Releases
|
(Dallas.CityRegions.Com, December 05, 2014 ) Dallas, TX -- Hepatocellular Carcinoma - Pipeline Review, H2 2014: Order report by calling ReportsnReports.com at +1 888 391 5441 OR send an email on sales@reportsandreports.com with your contact details.
Hepatocellular carcinoma (HCC, also called malignant hepatoma) is the most common type of liver cancer. Most cases of HCC are secondary to either a viral hepatitis infection (hepatitis B or C) or cirrhosis (alcoholism being the most common cause of hepatic cirrhosis).
Treatment options of HCC and prognosis are dependent on many factors but especially on tumour size and staging. Tumour grade is also important. High-grade tumours will have a poor prognosis, while low-grade tumors may go unnoticed for many years, as is the case in many other organs.
HCC is a relatively uncommon cancer in the United States. In countries where hepatitis is not common, most cancers of the liver are not primary HCC but metastasis (cancers spread from elsewhere in the body such as the colon). This report provides comprehensive information on the therapeutic development for Hepatocellular Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Hepatocellular Carcinoma and special features on late-stage and discontinued projects.
Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Complete report available at http://www.reportsnreports.com/reports/318781-hepatocellular-carcinoma-pipeline-review-h2-2014.html
Scope
The report provides a snapshot of the global therapeutic landscape of Hepatocellular Carcinoma
The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved in the therapeutics development for Hepatocellular Carcinoma and enlists all their major and minor projects
The report summarizes all the dormant and discontinued pipeline projects
A review of the Hepatocellular Carcinoma products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
A detailed assessment of monotherapy and combination therapy pipeline projects
Coverage of the Hepatocellular Carcinoma pipeline on the basis of target, MoA, route of administration and molecule type
Latest news and deals relating related to pipeline products
Inquire for discount on this report @ http://www.reportsnreports.com/contacts/discount.aspx?name=318781 (Original Price of the Report single user license at USD 2000)
Reasons to buy
Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop strategic initiatives by understanding the focus areas of leading companies
Identify and understand important and diverse types of therapeutics under development for Hepatocellular Carcinoma
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Devise corrective measures for pipeline projects by understanding Hepatocellular Carcinoma pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Buy a Copy of Report @ http://www.reportsnreports.com/purchase.aspx?name=318781
Fore more information on Pharmaceuticals Contact sales@reportsandreports.com / Call +1 888 391 5441 for further information on “Hepatocellular Carcinoma - Pipeline Review, H2 2014” report OR for any other market research and intelligence needs you may have for your business.
RnR Market Research
Ritesh Tiwari
18883915441
sales@rnrmarketresearch.com
Source: EmailWire.Com
|
|
|
|